盛德鑫泰(300881.SZ)擬出資9500萬元參與投資勤智德泰
格隆匯12月11日丨盛德鑫泰(300881.SZ)公佈,為充分藉助專業投資機構的專業資源及其投資管理優勢,促進公司長遠發展,公司及自然人周榕甬作為有限合夥人向深圳勤智德泰新科技創業投資企業(有限合夥)(以下簡稱“勤智德泰”、“投資基金”或“合夥企業”,投資於新材料領域及醫療大健康領域)增資,其中公司以自有資金出資9500萬元。
公司擬藉助專業投資機構的專業資源及其投資管理優勢,投資於新材料、醫療大健康等新科技領域早期項目或成熟期擬上市項目,洞察新科技領域相關產業各階段發展趨勢,力爭提升公司科技領域的核心競爭力,從而實現公司長期可持續發展的戰略目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.